Strategic Global Advisors LLC Acquires New Position in Insulet Corporation $PODD

Strategic Global Advisors LLC bought a new position in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,623 shares of the medical instruments supplier’s stock, valued at approximately $856,000.

Several other hedge funds and other institutional investors have also bought and sold shares of PODD. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Insulet by 26.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after buying an additional 9,206 shares during the period. OP Asset Management Ltd purchased a new stake in Insulet during the 1st quarter valued at $1,513,000. OneDigital Investment Advisors LLC bought a new stake in Insulet in the 2nd quarter worth $6,741,000. Strs Ohio grew its holdings in Insulet by 36.0% in the 4th quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier’s stock worth $6,447,000 after acquiring an additional 6,003 shares during the last quarter. Finally, Swedbank AB increased its position in shares of Insulet by 11.0% in the fourth quarter. Swedbank AB now owns 85,988 shares of the medical instruments supplier’s stock valued at $24,441,000 after acquiring an additional 8,500 shares during the period.

Insulet Trading Up 0.2%

NASDAQ:PODD opened at $143.38 on Thursday. The company has a 50-day moving average price of $154.52 and a 200-day moving average price of $182.09. The stock has a market cap of $9.94 billion, a price-to-earnings ratio of 26.80, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a 12 month low of $126.40 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the previous year, the company earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. TD Cowen dropped their target price on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a report on Thursday, August 6th. The Goldman Sachs Group restated a “buy” rating and set a $205.00 price target on shares of Insulet in a report on Wednesday, May 27th. Stifel Nicolaus lowered their price target on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. UBS Group dropped their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday, August 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Hold” and an average target price of $195.40.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.